MindMaze Therapeutics

MindMaze Home Rehab Data Shows 3x Training Dose Before Lite Launch

Geneva – October 14, 2026 -- MindMaze Therapeutics (SIX: MMTX) reported that home-based rehabilitation with its MindMotion platform raised total motor-training dose by a median factor of 3.0 versus usual outpatient therapy alone, with 84% of active training completed without direct therapist supervision.

The multi-site program, run with Vibra Healthcare, was presented at the American Congress of Rehabilitation Medicine (ACRM) in Washington, DC. The data arrive ahead of the company's MindMotion Lite launch, expected by year-end 2026.

Program covered 177 episodes across four Vibra outpatient sites

The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke. It had no control group. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision.

MindMaze Therapeutics to Launch Tablet-Based MindMotion Lite by Year-End 2026

Geneva – September 20, 2026 -- MindMaze Therapeutics (SIX: MMTX) will launch MindMotion Lite by the end of 2026, a tablet-based neurorehabilitation device designed to cut home deployment costs and expand access to intensive stroke and neurological therapy outside clinical settings.

Tablet format replaces bulky hardware for home use

MindMotion Lite delivers the full range of neurotherapeutic activities currently available on the company's MindMotion GO system through a tablet interface, reducing the hardware footprint required for in-home deployment. The device retains full-body rehabilitation training capacity while streamlining the user experience for patients managing therapy at home. It also supports teleconsultation and remote management, allowing clinicians to monitor and adjust treatment plans as patients continue therapy beyond the clinic.